Sichuan Hebang Biotechnology Corporation Limited
603077.SS · SHH
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | CN¥2 | CN¥2 | CN¥2 | CN¥2 |
| % Growth | -8.6% | 27.2% | -0.5% | – |
| Cost of Goods Sold | CN¥2 | CN¥2 | CN¥2 | CN¥2 |
| Gross Profit | CN¥0 | CN¥0 | CN¥0 | -CN¥0 |
| % Margin | 14.7% | 8.2% | 10.7% | -11.1% |
| R&D Expenses | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| G&A Expenses | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| SG&A Expenses | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| Sales & Mktg Exp. | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| Other Operating Expenses | CN¥0 | CN¥0 | CN¥0 | -CN¥0 |
| Operating Expenses | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| Operating Income | CN¥0 | CN¥0 | CN¥0 | -CN¥0 |
| % Margin | 6.9% | 1.6% | 1.2% | -18.6% |
| Other Income/Exp. Net | -CN¥0 | -CN¥0 | -CN¥0 | -CN¥0 |
| Pre-Tax Income | CN¥0 | CN¥0 | CN¥0 | -CN¥0 |
| Tax Expense | CN¥0 | CN¥0 | CN¥0 | -CN¥0 |
| Net Income | CN¥0 | CN¥0 | CN¥0 | -CN¥0 |
| % Margin | 2.1% | 1.8% | 0.7% | -11% |
| EPS | 0.005 | 0.005 | 0.002 | -0.024 |
| % Growth | 4% | 212.5% | 106.8% | – |
| EPS Diluted | 0.004 | 0.004 | 0.001 | -0.02 |
| Weighted Avg Shares Out | 8 | 8 | 8 | 8 |
| Weighted Avg Shares Out Dil | 10 | 10 | 10 | 9 |
| Supplemental Information | – | – | – | – |
| Interest Income | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| Interest Expense | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| Depreciation & Amortization | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| EBITDA | CN¥0 | CN¥0 | CN¥0 | -CN¥0 |
| % Margin | 7.4% | 12.5% | 16.7% | -6.2% |